DIBENAMINE is a nitrogen mustard derivative, first introduced by Nickerson1 in 1946, which possesses specific and highly potent sympatholytic and adrenolytic properties. Nickerson and Goodman2 subsequently elaborated upon the pharmacological characteristics of the substance. Ophthalmologic interest in the drug was stimulated in 1948 by Christensen, Swan, and Gould,3 who reported favorable effects in the treatment of acute glaucoma with Dibenamine.
This paper presents certain experimental data concerned with the mechanism of action of Dibenamine in lowering intraocular pressure and our experiences with the drug in the treatment of a small number of patients with acute glaucoma.
PURPOSE OF EXPERIMENTS
The way in which Dibenamine lowers the intraocular pressure in glaucoma has never been determined. We felt that several possibilities should be investigated and devoted our experimental studies to the following factors: (1) alterations in the permeability of the blood-aqueous barrier; (2) changes in rate of flow of
DeLONG SL, SCHEIE HG. DIBENAMINE: An Experimental and Clinical Study. AMA Arch Ophthalmol. 1953;50(3):289–298. doi:10.1001/archopht.1953.00920030296005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: